Schonfeld Strategic Advisors LLC Buys 47,353 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Schonfeld Strategic Advisors LLC grew its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 402,955 shares of the company's stock after purchasing an additional 47,353 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.53% of Nurix Therapeutics worth $7,592,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Barclays PLC lifted its stake in Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Nurix Therapeutics by 52.4% during the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company's stock valued at $2,766,000 after buying an additional 42,315 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Nurix Therapeutics during the 3rd quarter worth $7,879,000. JPMorgan Chase & Co. grew its stake in shares of Nurix Therapeutics by 85.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after acquiring an additional 31,352 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Nurix Therapeutics by 31.1% in the 4th quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock worth $567,000 after acquiring an additional 7,141 shares during the last quarter.

Nurix Therapeutics Trading Down 2.9 %

NRIX stock traded down $0.33 during midday trading on Monday, hitting $10.94. The company had a trading volume of 525,663 shares, compared to its average volume of 886,803. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The stock has a market cap of $834.02 million, a price-to-earnings ratio of -3.79 and a beta of 2.23. The stock's 50 day moving average price is $12.03 and its 200 day moving average price is $17.89.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same quarter in the prior year, the company posted ($0.76) EPS. Analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NRIX. Wells Fargo & Company lowered their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Needham & Company LLC reissued a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Morgan Stanley raised their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Finally, JPMorgan Chase & Co. lowered their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Nurix Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $30.44.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer now owns 33,724 shares in the company, valued at approximately $382,092.92. This trade represents a 15.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now owns 61,516 shares in the company, valued at approximately $707,434. This represents a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,838 shares of company stock valued at $221,500 over the last ninety days. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.